The World’s Definitive Degrader & Proximity-Based Drugs Event

After a decade of innovation, the TPD field achieved its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation unleashed a new wave of innovative approaches and pushed TPD to a new inflection point. Already, the headwinds had reversed with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone.

However, following the risk-averse funding environment of 2025, continued positive clinical data remained key to regaining investor confidence and pharma interest. That's why the 9th TPD & Induced Proximity Summit returned as the globe’s definitive forum to help attendees gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development, it was designed to help participants discover the best novel targets, optimize degrader profiles, attract funding and partnerships, and accelerate pipelines to the clinic and beyond.

Uniting leaders from the likes of Arvinas, Revolution Medicines, Foghorn Therapeutics, BMS, Amgen, C4 Therapeutics, Neomorph and more, this end-to-end forum equipped attendees with the data, insights and connections to advance their own induced proximity pipelines and transform therapeutic strategies across oncology, immunology and neurodegeneration.